Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?

Pharmaceutical Science and Technology Today

Volumn 2, Issue 11, 1999, Pages 441-449

  Duncan, Ruth ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CAMPTOTHECIN; DAUNORUBICIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GOSERELIN; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; REVIEW; TUMOR VASCULARIZATION;

EID: 0033231137     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1461-5347(99)00211-4     Document Type: Review

References (88)

1. Forssen, E.A. (1997) Adv. Drug Deliv. Rev. 24, 133-150
2. Winterhalter, M. et al. (1997) Adv. Drug Deliv. Rev. 24, 165-177
3. Thomas, F. (1998) Scrip Magazine May, 42-43
4. Duncan, R. (1992) Anti-Cancer Drugs 3, 175-210
5. Bokkel-Huniunk, W. et al. (1998) Proc. 3rd Int'l. Symp. on Polymer Therapeutics, 7-9 January, London, UK, p. 12
6. Caiolfa, V.R. et al. (1999) Proc. Intl. Symp. on Recent Adv. in Drug Deliv. Systems, 22-25 February, Salt Lake City, UT, USA, p. 46
7. Connors, T.A. (1996) Ann. Oncol. 7, 445-452
8. Mason, P. (1998) Pharm. J. 260, 382-385
9. Hill, B.T. (1996) Anti-Cancer Drugs 7, 1-185
10. Folkman, J. (1995) Adv. Cancer Res. 43, 175-203
11. Lundberg, A.S. and Weinberg, R.A. (1999) Eur. J. Cancer 35, 531-539
12. Sandhu, J.S., Keating, A. and Hozumi, N. (1997) Crit. Rev. Biotechnol. 17, 307-326
13. Crooke, S.T. (1998) Biotechnol. Engineer. Rev. 15, 121-157
14. McNeish, I.A. et al. (1997) Adv. Drug Deliv. Rev. 26, 173-184
15. Robert K.Y., Cheng, Z. and Cheng C.C. (1989) Meth. and Find Exp. Clin. Pharmacol. 11, 439-529
16. Word, J.A. et al. (1989) J. Andrology 10, 478-486
17. Brown, D.M., Ed., Drug Delivery Systems in Cancer Treatment Humana Press, Totowa, NJ, USA (in press)
18. Nucci, M.L., Shorr, R. and Abuchowski, A. (1991) Adv. Drug Deliv. Rev. 6, 133-151
19. Fuertges, F. and Abuchowski, A. (1990) J. Control. Release 11, 139-148
20. Jain, R. (1998) Nat. Med. 4, 655-657
21. Onkos Study (1997) Drug Delivery Systems, pp. 1-109, Descision Resources Inc., Waltham, USA
22. Denekamp, J. (1987) Acta Radiol. Oncol. 23, 217-225
23. Folkman, J. (1990) J. Natl. Cancer Inst. 82, 4-6
24. Maragoudakis, M.E., ed., (1998) Angiogenesis: Models Modulators and Clinical Applications Plenum Press, New York, USA
25. Konerding, M.A. et al. (1998) in Angiogenesis: Models Modulators and Clinical Applications (Maragoudakis, M.E., ed.), pp. 429-447, Plenum Press, New York, USA
26. O'Reilly, M. et al. (1996) Nat. Med. 2, 689-692
27. Chaplin, D.J., Pettit, G.R. and Hill, S.A. (1999) Anticancer Res. 19, 189-195
28. Ingber, D.E. (1997) in Cancer Therapeutics: Experimental and Clinical Agents (Teicher, B., ed.), Humana Press, Totowa, NJ, USA
29. Ran, S. et al. (1998) Cancer Res. 58, 4646-4653
30. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) Science 279, 377-380
31. Maeda, H. and Matsumura, Y. (1989) CRC Crit. Rev. Ther. Drug Carrier Sys. 6, 193-210
32. Onetto, N. et al. (1995) Proc. EORTC Early Drug Development Meeting (Pavlidis, N. ed.), 21-24 June, Corfu, National Library of Greece, p. 59
33. Jain, R.K. (1989) J. Natl. Cancer Inst. 81, 570-576
34. Weistein, J.N. et al. (1987) Ann. New York Acad. Sci. U.S.A 507, 199-210
35. Matsumura, Y. and Maeda, H. (1986) Cancer Res. 6, 6387-6392
36. Muggia, F.M. (1999) Clin. Cancer. Res. 5, 7-8
37. Seymour, L.W. et al. (1995) Eur. J. Cancer 5, 766-770
38. Noguchi, Y. et al. (1998) Jpn. J. Cancer Res. 89, 307-314
39. Yuan, F. et al. (1994) Cancer Res. 54, 3352-3356
40. Yuan F. et al. (1995) Cancer Res. 55, 3752-3756
41. Yokoyama, M. et al. (1991) Cancer Res. 51, 3229-3236
42. Gianasi, E. et al. (1999) Eur. J. Cancer 35, 994-1002
43. Malik, N., Evagorou, E.G. and Duncan, R. Anti-cancer Drugs (in press)
44. Fukumura, D. et al. (1997) Am. J. Pathol. 151, 679-688
45. Jain, R.K. (1997) Adv. Drug Deliv. Rev. 26, 71-90
46. Hobbs, S.K. et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 4607-4612
47. Yuan, F. et al. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 14765-14770
48. Sat, Y.N. et al. (1999) Proc. Int'l. Symp. Control. Rel. Bioact. Mater. 26, 241
49. Duncan, R. and Sat, Y.N. (1998) Ann. Oncol. 9, 149
50. Northfelt, D.W. et al. (1996) J. Clin. Pharmacol. 36, 55-63
51. Duncan, R. (1997) Chem. Ind. 7, 262-264
52. Ringsdorf, H. (1975) J. Polym. Sci., Polym. Symp. 51, 135-153
53. Seymour, L.W. (1991) J. Bioactive Compatible Polymers 6, 178-216
54. Duncan, R., Dimitrijevic, S. and Evagorou, E.G. (1996) S.T.P. Pharma Sci. 6, 237-263
55. Brocchini, S. and Duncan, R. (1999) in Encyclopedia of Controlled Release (Mathiowitz E., ed.), pp. 786-816, Wiley, New York, USA
56. Duncan, R. et al. (1988) Br. J. Cancer 57, 147-156
57. Duncan, R. et al. (1992) J. Control. Release 19, 331-346
58. Duncan, R. et al. (1991) J. Control. Release 16, 121-136
59. Krinick, N.L. et al. (1994) J. Biomat. Sci-Polymer Ed. 5, 303-324
60. Dimitrijevic, S. and Duncan, R. (1998) J. Bioact. Compat. Polym. 13, 165-178
61. Duncan, R. et al. (1984) Makromol. Chem. 184, 1997-2008
62. Freidrich, B. et al. (1999) Eur. J. Cancer 35, 138-144
63. Evagorou, E.G. et al. (1998) Proc. 3rd Intl. Symp. on Polymer Therapeutics: Laboratory to Clinic, 7-9 January, London, UK, p. 71
64. Seymour, L.W. et al. (1994) Br. J. Cancer 70, 636-641
65. Vasey, P. et al. (1999) Clin. Cancer Res. 5, 83-94
66. Kerr, D. et al. (1998) Proc. 3rd Int'l. Symp. on Polymer Therapeutics, 7-9 January, London, UK, p. 23
67. Pimm, M.V. et al. (1993) J. Drug Targeting 1, 131-152
68. Pimm, M.V. et al. (1996) J. Drug Targeting 3, 375-383
69. Julyan, P.J. et al. (1999) J. Control. Release 57, 281-290
70. Lattime, E.C. and Gerson, S.L., eds, (1998) Gene Therapy of Cancer, Academic Press, London, UK
71. Mahato, R.I. Takakura, Y. and Hashida, M. (1997) J. Drug Targeting 4, 337-357
72. Kabanov, A.V., Felgner, P.L. and Seymour, L.W., eds, (1998) Self-assembling Complexes for Gene Delivery John Wiley & Sons Ltd., Chichester, UK
73. Wu, G. and Wu, C. (1987) J. Biol. Chem. 262, 4429-4432
74. Boussif, O. et al. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 7297-7310
75. Ferruti, P., Duncan, R. and Richardson, S. (1998) in Targeting of Drugs: Stealth Therapeutic Systems (Gregoriadis, G. and McCormack, B., eds), pp. 207-224, Plenum Press, New York, USA
76. Oupicky, D., Konak, C. and Ulbrich, K. (1999) J. Biomater. Sci. Polymer Ed. 10, 573-590
77. Remy, J-S. et al. (1998) Adv. Drug. Deliv. Rev. 30, 85-95
78. Richardson, S.C.W., Ferruti, P. and Duncan, R. J. Drug Targeting (in press)
79. Richardson, S.C.W. et al. (1999) Proc. Int'l. Symp. Control. Rel. Bioact. Mater. 26, 251
80. Zanta, M.A., Belguise-Valladier, P. and Behr, J.P. (1999) Proc. Natl. Acad. Sci. USA 96, 91-96
81. Sat, Y.N. et al. (1999) Proc. Am. Assoc. Cancer Res. 40, 41
82. Li, C. et al. (1999) Proc. 9th Int'l. Symp. on Recent Advances in Drug Delivery Systems, 22-25 February, Salt Lake City, UT, USA, pp. 222-223
83. Wu, J., Akaike,T. and Maeda, H. (1998) Cancer Res. 58, 159-165
84. De Jong, J. et al. (1992) J. Clin. Oncol. 10, 1897-1906
85. Danauser-Reidl, S. et al. (1993) Invest. New Drugs 11, 187-195
86. Kattan, J. et al. (1992) Invest. New Drugs 10, 191-199
87. Garcia, A.A. et al. (1998) Ann. Oncol. 9, 1131-1133
88. Fossa, S.D., Aass, N. and Paro, G. (1998) Eur. J. Cancer 34, 1131-1132